Hsu et al. revealed that PR-619 enhanced cisplatin-induced cytotoxicity and alleviated cisplatin resistance in the cisplatin-resistant T24/R (cisplatin-resistant BC cells) cell line and concurrently suppressed c-Myc expression [9]. Here, MYC is linked to breast cancer.